Return to Results

A Phase 3, Open Label, Multicenter Study for the Assessment of Myocardial Perfusion Using Positron Emission Tomography (PET) Imaging of Flurpiridaz F18 Injection in Patients With Suspected or Known Co

new search

Trial Conditions
  • Coronary Artery Disease
What is the purpose of this trial?

The primary objective of the study is to assess the diagnostic efficacy (specificity and sensitivity) of flurpiridaz F18 injection PET myocardial perfusion imaging (MPI) compared to single photon emission computed tomography (SPECT) MPI in the detection of significant coronary artery disease (CAD) as defined by invasive coronary angiography (ICA) or a documented history of Myocardial Infarction (MI).

Date & Status


Who can Participate?


18 and older



Inclusion Criteria:

Invasive Coronary Angiography. Men or Women age 18 or older - see protocol for additional

Exclusion Criteria:

Women who are pregnant, lactating, or of child bearing potential who are not practicing
birth control.

Unstable cardiac status. History of coronary artery bypass graft. History of PCI within
the past six months. See protocol for additional details.

Gender: Both
Steward Physician(s)
  • Cesare Orlandi, MD
Trial Interventions
  • Flurpiridaz F18
Physician Researcher

Investigator Name:

  • Cesare Orlandi, MD

Other Information

Sponsor: Lantheus Medical Imaging
Phase: Phase 3
Trial ID: NCT01347710
Volunteers:  Not Accepting Healthy Volunteers

new search

Connect with Steward

Visit Our Twitter Feed Visit Our Facebook Page Email This Page Print This Page

Subscribe to our patient e-newsletter

Copyright © 2015 Steward Health Care
Connect Healthcare Panacea CMS Solutions